Results 11 to 20 of about 4,836 (234)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy [PDF]

Antibiotics, 2021
(1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models.
Soo Min Jang, Lenar Yessayan, Michael Dean, Gabrielle Costello, Ravi Katwaru, Bruce A. Mueller   +5 more
doaj   +3 more sources

AmpC β-lactamase induction by avibactam and relebactam [PDF]

Journal of Antimicrobial Chemotherapy, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +6 more sources

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus [PDF]

Scientific Reports, 2020
Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic ...
Cox, Jonathan A.G., Desai, Maya, Harrison, James, Lambert, Peter, Lopeman, Rose C., Rathbone, Dan   +5 more
core   +4 more sources

Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical <i>Klebsiella pneumoniae</i> ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions. [PDF]

Antimicrob Agents Chemother
Two episodes of imipenem/relebactam and ceftazidime/avibactam co-resistant Klebsiella pneumoniae infections were identified in a Chinese hospital with an 8-month interval.
Fu Y, Zhang Y, Zhao J, Xie J, Kong H, Yang T, Chen W, Xu M.   +7 more
europepmc   +2 more sources

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials. [PDF]

BMC Infect Dis
Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so ...
Lei W, Duan Y, Xin M, Tian M, Xu J.
europepmc   +2 more sources

Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study [PDF]

Open Forum Infectious Diseases
Background: Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa ...
Adams, Jenna, Albarillo, Fritzie, Antosz, Kayla, Barber, Katie E., Benefield, Russell, Biagi, Mark, Caniff, Kaylee E., Carlson, Travis J., Carr, Amy, Chandler, Elisabeth, Chang, Mei, Eubank, Taryn A., Frens, Jeremy, Garey, Kevin W., Guo, Yi, Hayes, Jillian, Hobbs, Athena L V, Justo, Julie Ann, Krekel, Tamara, Kufel, Wesley D., Kunz Coyne, Ashlan J., Li, Rosanna, Lucas, Kristen, Mercuro, Nicholas, Moore, W Justin, Raux, Brian, Rebold, Nicholas, Ross, Jennifer, Rybak, Michael J., Sanders, James, Stefanos, Sylvia, Tran, Nikki, Venugopalan, Veena, Xhemali, Xhilda, Zeitler, Kristen   +34 more
core   +3 more sources

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan

Microbiology Spectrum, 2022
Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections.
Dai Kurihara, Satoru Matsumoto, Naoko Kishi, Yoshikazu Ishii, Masahiko Mori   +4 more
doaj   +3 more sources

Phenotypic profile and molecular mechanism of resistance in carbapenemase-producing Enterobacterales and <i>Pseudomonas aeruginosa</i> isolates from Brazilian hospitals: implications for the introduction of imipenem-relebactam. [PDF]

Front Microbiol
Background/Objectives Carbapenemase-producing Enterobacterales and P. aeruginosa are critical threats to global public health, especially in high-burden regions such as Brazil.
Kurtz P, Del Peloso PF, Pribul BR, Albuquerque AM, Antunes BBP, Ramos GV, Bozza FA.   +6 more
europepmc   +2 more sources

Restoring Control: Real-World Success with Imipenem-Relebactam in Critical MDR Infections-A Multicenter Observational Study. [PDF]

Pathogens
Background: Multidrug-resistant (MDR) Gram-negative infections, particularly those caused by carbapenem-resistant Enterobacterales (CRE) and difficult-to-treat Pseudomonas aeruginosa (DTR-Pa), present a growing global healthcare challenge, especially in ...
Marino A, Pipitone G, Venanzi Rullo E, Cosentino F, Ippolito R, Costa R, Bagarello S, Russotto Y, Iaria C, Cacopardo B, Nunnari G.   +10 more
europepmc   +2 more sources

In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex [PDF]

The Cell Surface, 2021
Infections resulting from Mycobacterium abscessus are increasing in prevalence worldwide, with the greatest risk posed to patients with underlying respiratory conditions.
James Harrison, John A. Weaver, Maya Desai, Jonathan A.G. Cox   +3 more
doaj   +3 more sources